Search

Objective: To investigate the frequency of pulmonary hypertension (PH) and clinical parameters associated with PH in sarcoidosis patients. Methods: A prospective, observational study was performed on 246 consecutive Japanese sarcoidosis [...]

Background: FE[V.sub.1] is regarded as the most significant correlate of survival in COPD and is used as a measure of disease severity in the staging of COPD. Recently, however, the [...]

Study objective: To determine the physiologic factors that influence the health-related quality of life (HRQL) in patients with stable COPD and to identify the factors that most influence HRQL. Methods: [...]

Study objective: To determine the additive effect of oral theophylline in patients with stable COPD who received both inhaled salbutamol, 400 μg, and ipratropium bromide, 80 μg, four times daily [...]

Several studies have suggested that anticholinergics are at least equal to or may be superior to beta agonists in the treatment of stable COPD. However, since most previous studies have [...]

Inhaled anticholinergics may be the first-line therapy for stable COPD. However, the effect of inhaled anticholinergic agents on exercise capacity is still controversial. Fourteen patients with stable COPD (age, 64.6±5.9 [...]

In our study of 52 patients with idiopathic pulmonary fibrosis (IPF), we found that the incidence of clubbing of the fingers was significantly more frequent in male than in female [...]

Oxitropium bromide is a novel anticholinergic bronchodilator agent. The purpose of this study was to compare the bronchodilating and cardiovascular effects of oxitropium (0.2 mg), fenoterol (0.4 mg), combined oxitropium and fenoterol (0.2 mg and 0.4 mg, respectively) over a 10-h test period. Fourteen patients with chronic obstructive pulmonary disease (COPD) ([FEV.sub.1], 0.95 ± 0.38L) were studied in a randomized, double-blind, placebo-controlled trial. Combined oxitropium and fenoterol produced significantly greater improvements in [FEV.sub.1] over a time span of 15 min to 10 h and in the area under the time-[FEV.sub.1] curve (AUC) than either oxitropium or fenoterol alone. The effects of oxitropium on both [FEV.sub.1] and AUC values were similar to those of fenoterol. Oxitropium resulted in a greater increase in [FEV.sub.1] than the placebo even after 10 h. In contrast, fenoterol produced a significant improvement in the [FEV.sub.1] for only 15 min to 4 h. Oxitropium showed no adverse cardiovasular effects, whereas fenoterol was associated with an increased heart rate at 15 min and 1 h after the administration. We conclude that oxitropium bromide is an effective and safe bronchodilator for even elderly patients with COPD. (Chest 1993; 104:1743-47) AUC = area under the time-[FEV.sub.1] curve; MDI = metered-dose inhaler, Bronchodilating therapy is an important component of the treatment for chronic obstructive pulmonary disease (COPD). Theophylline, [β.sub.2]-adrenergic agonists, and anticholinergics have all been used in patients with COPD. The efficacy [...]

The purpose of this study was to evaluate the role of high-resolution computed tomography (HRCT) in the clinical diagnosis of diffuse infiltrative lung disease (DILD). Diagnostic accuracy was compared using [...]

To investigate the additive effect of oral theophylline on combined inhaled anticholinergic agent and [β.sub.2]-agonist therapy, 12 patients with stable COPD (64.6 ± 5.9 years) completed a randomized, double-blind placebo-controlled [...]

We compared the doubling time of fibroblasts derived from idiopathic pulmonary fibrosis (usual interstitial pneumonia) (IPF [UIP]) lung tissues and control fibroblasts, cultured in usual growth medium, and examined the [...]

The clinical features of 34 Japanese patients with bronchiolitis obliterans organizing pneumonia (BOOP) are discussed. Thirty-two patients (94 percent) had symptoms of cough, fever, or dyspnea. On chest roentgenograms, bilateral [...]

Bronchiolitis obliterans with organizing pneumonia (BOOP) is a clinicopathologic entity.[1] It is pathologically defined as granulation tissue plugs within lumens of small airways, sometimes with complete obstruction of small airways [...]

Study objectives: To compare categorizations of the level of dyspnea with the staging of disease severity as defined by the [FEV.sub.1] in representing how the health-related quality of life (HRQOL) [...]

Background: The benefits of inhaled corticosteroids in the management of COPD are less apparent than they are in asthma therapy, and the potential for adverse systemic effects of high-dose inhaled [...]